No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
MRVI240719C7500
- 1.05
- +0.35+50.00%
15min DelayClose Jul 15 15:59 ET
1.05High1.05Low
1.05Open0.70Pre Close1 Volume34 Open Interest7.50Strike Price105.00Turnover233.90%IV-2.40%PremiumJul 19, 2024Expiry Date1.26Intrinsic Value100Multiplier4DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.7711Delta0.1366Gamma5.48Leverage Ratio-0.0824Theta0.0006Rho4.22Eff Leverage0.0029Vega
Intraday
- 5D
- Daily
News
Maravai LifeSciences To Host Earnings Conference Call on Wednesday, August 7, 2024
SAN DIEGO, July 10, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its
Express News | Goldman Sachs Maintains Neutral on Maravai LifeSciences, Lowers Price Target to $7
Maravai LifeSciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/09/2024 -4.89% Goldman Sachs $8 → $7 Maintains Neutral 05/09/2024 35.87% Baird $8 → $10 Maintains
Maravai Lifesciences Releases 2023 Environmental, Social and Governance (ESG) Report
- Highlights progress across four priority areas and commitment to environmentally and socially responsible growth. - Conducted first stakeholder assessment to identify and prioritize ESG issues that are most important
Take Care Before Jumping Onto Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Even Though It's 35% Cheaper
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) shares have had a horrible month, losing 35% after a relatively good period beforehand. The drop over the last 30 days has capped off a tough year
Applied DNA and Alphazyme Conclude Linea(TM) RNAP Manufacturing Scale-up Project, Deliver Substantial Improvement in Linea(TM) IVT Platform Economics
- Project Results in over 70% Reduction in Linea RNAP Manufacturing Cost to Yield a Material Improvement in Linea IVT Platform Profitability -- Applied DNA Secures Commercial Linea RNAP Quantity Sufficient to Support
Comments
Despite Maravai LifeSciences Holdings' significant liabilities, it has net cash, indicating a light debt load. However, its pre-interest and tax loss and declining revenue raise future earnings and balance sheet health concerns.
Is Maravai LifeSciences Holdings (NASDAQ:MRVI) Using Debt In A Risky Way? 1
While Maravai LifeSciences Holdings displays a low ROE, its ability to expand net income considerably due to efficient management and high profit reinvestment is a positive sign. Current analyst forecasts suggest continued earnings growth for the company.
While Maravai LifeSciences Holdings displays a low ROE, its ability to expand net income considerably due to efficient management and high profit reinvestment is a positive sign. Current analyst forecasts suggest continued earnings growth for the company.
While Maravai LifeSciences Holdings displays a low ROE, its ability to expand net income considerably due to efficient management and high profit reinvestment is a positive sign. Current analyst forecasts suggest continued earnings growth for the company.
While Maravai LifeSciences Holdings displays a low ROE, its ability to expand net income considerably due to efficient management and high profit reinvestment is a positive sign. Current analyst forecasts suggest continued earnings growth for the company.
Read more